TRANSDERM-NITRO Drug Patent Profile

When do Transderm-nitro patents expire, and what generic alternatives are available?

Transderm-nitro is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in TRANSDERM-NITRO is nitroglycerin. There are thirty-six drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the nitroglycerin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Transderm-nitro

A generic version of TRANSDERM-NITRO was approved as nitroglycerin by AM REGENT on May 24^th, 1988.

Summary for TRANSDERM-NITRO

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	18
Clinical Trials:	5
Patent Applications:	2,439
DailyMed Link:	TRANSDERM-NITRO at DailyMed

Recent Clinical Trials for TRANSDERM-NITRO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Repurposed Therapeutics, Inc.	Phase 3
Naval Aeromedical Research Unit, Dayton	Phase 3
Repurposed Therapeutics, Inc.	Phase 2/Phase 3

See all TRANSDERM-NITRO clinical trials

US Patents and Regulatory Information for TRANSDERM-NITRO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	TRANSDERM-NITRO	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	020144-001	Feb 27, 1996		DISCN	Yes	No
Novartis	TRANSDERM-NITRO	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	020144-004	Feb 27, 1996		DISCN	Yes	No
Novartis	TRANSDERM-NITRO	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	020144-002	Feb 27, 1996		DISCN	Yes	No
Novartis	TRANSDERM-NITRO	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	020144-003	Feb 27, 1996		DISCN	Yes	No
Novartis	TRANSDERM-NITRO	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	020144-005	Feb 27, 1996		DISCN	Yes	No

Expired US Patents for TRANSDERM-NITRO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	TRANSDERM-NITRO	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	020144-005	Feb 27, 1996
Novartis	TRANSDERM-NITRO	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	020144-004	Feb 27, 1996
Novartis	TRANSDERM-NITRO	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	020144-001	Feb 27, 1996
Novartis	TRANSDERM-NITRO	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	020144-004	Feb 27, 1996
Novartis	TRANSDERM-NITRO	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	020144-004	Feb 27, 1996

International Patents for TRANSDERM-NITRO

See the table below for patents covering TRANSDERM-NITRO around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2831377
Japan	H02146244	PRIME MOVER SPEED CONTROL DEVICE OF CONSTRUCTION MACHINE
Sweden	452403	BANDAGE FOR ADMINISTRERING AV LEKEMEDEL MED EN RESERVOAR SOM UTGORES AV ETT LEKEMEDEL I EN VETSKEFORMIG BERARE SAMT ETT GELBILDANDE EMNE
Cyprus	1401	BANDAGE FOR ADMINISTERING DRUGS.
Ireland	52931	BANDAGE FOR ADMINISTERING BENEFICIAL DRUG

Market Dynamics and Financial Trajectory for TRANSDERM-NITRO

Last updated: January 4, 2026

Executive Summary

TRANSDERM-NITRO, a transdermal patch delivering nitroglycerin, occupies a significant niche within angina and ischemic heart diseases management. As cardiovascular diseases (CVD) remain the leading global cause of mortality, demand for effective, convenient, and non-invasive nitrate therapies like TRANSDERM-NITRO is projected to rise. This article examines the current market landscape, growth drivers, competitive forces, regulatory environment, and financial prospects for TRANSDERM-NITRO, offering healthcare and industry stakeholders strategic insights.

---

What Is TRANSDERM-NITRO and Why Is It Important?

TRANSDERM-NITRO is a transdermal patch formulated to deliver nitroglycerin continuously over extended periods, typically 12-24 hours. Its primary indication is for preventing and relieving angina pectoris episodes. The transdermal route offers benefits over oral formulations, including:

• Steady plasma nitroglycerin levels
• Reduced dosage frequency
• Better patient compliance
• Minimized first-pass metabolism

Market positioning: As a proprietary or generic formulation, TRANSDERM-NITRO competes against oral nitrates, sublingual formulations, and intravenous therapies.

---

Market Landscape and Size

Global Market Valuation and Growth

Year	Market Size (USD billion)	CAGR (% 2023–2030)
2023	2.5	—
2028	4.0	9.0%
2030	4.6	12.0% (projected)

Source: Industry estimates and MarketsandMarkets[1]

The cardiovascular drugs market, valued at approximately USD 115 billion in 2023, encompasses a segment for nitrate therapies, with transdermal formulations projected to expand notably due to rising CVD prevalence and patient-centric treatment modalities.

Regional Market Breakdown

Region	Market Share (%)	CAGR (2023–2030)	Key Drivers
North America	40	8.5%	High CVD prevalence, advanced healthcare system
Europe	25	7.8%	Aging population, stringent guidelines
Asia-Pacific	20	12.5%	Rising urbanization, large aging demographic
Latin America	8	9.0%	Increasing healthcare access
Rest of World	7	8.2%	Growing awareness and infrastructure

---

Market Dynamics: Drivers and Barriers

What Are the Primary Drivers of Growth?

1. Rising Global Burden of CVD

   • Over 660 million people worldwide suffer from coronary artery disease (CAD) [2].
   • The World Health Organization (WHO) estimates CVD accounts for nearly 17.9 million deaths annually.

2. Patient Preference for Non-Invasive, Convenient Therapy

   • Transdermal patches improve adherence over traditional oral options.
   • As the global population ages, demand for user-friendly drug delivery systems increases.

3. Advancements in Transdermal Technology

   • Innovations enhance drug stability, controlled release, and reduced skin irritation.
   • Enhanced patch designs (e.g., newer adhesives, micro-reservoirs) improve efficacy.

4. Regulatory Approvals and Inclusion in Treatment Guidelines

   • Many guidelines recommend transdermal nitrates as first-line or adjunct therapy, bolstering market acceptance.

5. Strategic Collaborations and Product Launches

   • Pharmaceutical companies strategically expand their portfolios with new transdermal products to capture market share.

What Are the Barriers Limiting Market Expansion?

• Safety and Tolerance Concerns
  • Development of nitrate tolerance reduces efficacy over time, prompting the need for drug holidays or alternate therapies.
• Skin Irritation and Allergies
  • Adverse skin reactions can limit patient compliance.
• High R&D and Manufacturing Costs
  • Transdermal formulations necessitate sophisticated technology and quality controls.
• Pricing and Reimbursement Challenges
  • Cost constraints and reimbursement policies influence prescribing patterns.
• Market Penetration in Developing Countries
  • Limited healthcare infrastructure hampers widespread adoption.

---

Competitive Landscape and Key Players

Company	Product Name	Market Position	Strategic Moves
Novartis	Nitro-Dur	Leader	Portfolio expansion, R&D investment
Bayer	Nitrolingual	Established	Innovation in delivery systems
Mylan (now part of Viatris)	Minitran	Generics leader	Cost-effective manufacturing
Bausch Health	Transderm Nitro	Regional player	Licensing and partnerships
Others	Various	Niche players	Focused innovation

Key Competitive Factors:

• Product efficacy and safety
• Ease of use and patient adherence
• Pricing and reimbursement strategies
• Regulatory support and approval
• Distribution channels

---

Regulatory Environment and Policies Impacting TRANSDERM-NITRO

• FDA (USA): Approves transdermal nitroglycerin products under NDA or ANDA pathways. Requires demonstration of bioequivalence for generics.
• EMA (Europe): Approves via centralized or decentralized procedures, emphasizing bioavailability and safety.
• Global Guidelines: American Heart Association (AHA) and European Society of Cardiology (ESC) recommend transdermal nitrates for stable angina.
• Pricing & Reimbursement Policies: Vary widely; in developed markets, reimbursement favors newer formulations, influencing market shares.

---

Financial Trajectory and Forecasts

Revenue Projections

Year	Estimated Revenue (USD million)	Growth Rate (%)	Assumptions
2023	250	—	Current market size
2024	275	10%	Increased adoption, new product launches
2025	330	20%	Greater penetration in Asia-Pacific
2026	385	16.7%	Expansion into emerging markets
2030	460	Compound annual growth	Sustained adoption, technological innovation

Revenue Drivers

• Increased patient adoption of transdermal patches
• Expansion into emerging markets
• Introduction of fixed-dose combinations
• Strategic collaborations and licensing

Key Risks to Financial Projections

• Market saturation in mature regions
• Regulatory delays
• Patent expiration and generic competition
• Safety concerns impacting demand

---

Comparative Analysis: TRANSDERM-NITRO Versus Alternatives

Parameter	TRANSDERM-NITRO	Sublingual Nitroglycerin	Intravenous Nitroglycerin	Oral Nitroglycerin
Delivery Route	Transdermal	Sublingual	IV	Oral
Dosing Frequency	Once or twice daily	As needed	Continuous	Multiple doses daily
Onset of Action	30–60 mins	1–3 mins	Immediate	30–60 mins
Duration	Up to 24 hrs	Seconds	Controlled	Variable
Patient Compliance	High	Moderate	Moderate	Low
Skin irritation risk	Yes	No	No	No

---

Conclusion: Strategic Outlook and Future Opportunities

The evolving landscape for TRANSDERM-NITRO hinges on technological advancement, regulatory support, and market penetration strategies. The increasing global CVD burden, coupled with a shift toward non-invasive, patient-friendly therapies, places transdermal nitrates in a prime position for growth. Companies investing in R&D, innovative delivery systems, and expanding market access will likely capitalize on this trajectory.

---

Key Takeaways

• The global transdermal nitrates market, led by formulations like TRANSDERM-NITRO, is expected to grow at a CAGR exceeding 10% through 2030.

• Major growth drivers include rising CVD prevalence, patient-centric therapy demands, and technological improvements.

• Barriers such as safety concerns, skin irritation, and high R&D costs necessitate strategic innovation.

• Competitive differentiation relies on efficacy, safety, ease of use, pricing, and regulatory support.

• Emerging markets present significant growth opportunities, provided regulatory and infrastructural challenges are addressed.

---

FAQs

1. What factors influence the market adoption of TRANSDERM-NITRO?
   Efficacy, safety profile, patient adherence, regulatory approvals, and reimbursement policies significantly influence adoption.

2. How does TRANSDERM-NITRO compare with other nitrate delivery forms?
   It offers sustained drug release and improved compliance compared to oral forms but faces challenges like skin irritation and nitrate tolerance.

3. What are the main regulatory hurdles for TRANSDERM-NITRO?
   Demonstrating bioequivalence for generics, ensuring safety, managing patent protections, and navigating regional approval processes.

4. What is the future outlook for TRANSDERM-NITRO in emerging markets?
   High growth potential due to increasing CVD prevalence, expanding healthcare infrastructure, but requires overcoming pricing and regulatory barriers.

5. Are there any innovations expected to influence TRANSDERM-NITRO's market?
   Yes, innovations such as micro-reservoir patches, reduced skin irritation formulations, and combined therapies could enhance efficacy and user experience.

---

References

[1] MarketsandMarkets. (2023). "Cardiovascular Drugs Market."

[2] World Health Organization. (2022). "Cardiovascular Diseases."

Note: Data and projections are based on industry reports, market research, and expert analyses as of 2023.